NWQ Investment Management Company LLC raised its holdings in shares of AstraZeneca plc (NYSE:AZN) by 3.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 595,499 shares of the company’s stock after buying an additional 17,624 shares during the quarter. NWQ Investment Management Company LLC’s holdings in AstraZeneca were worth $20,664,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Pinnacle Wealth Planning Services Inc. purchased a new stake in shares of AstraZeneca during the fourth quarter worth $101,000. Valeo Financial Advisors LLC purchased a new stake in shares of AstraZeneca during the third quarter worth $133,000. Delpha Capital Management LLC purchased a new stake in shares of AstraZeneca during the fourth quarter worth $152,000. Calton & Associates Inc. purchased a new stake in shares of AstraZeneca during the fourth quarter worth $181,000. Finally, Wealthcare Advisory Partners LLC purchased a new stake in shares of AstraZeneca during the third quarter worth $184,000. 15.15% of the stock is owned by institutional investors and hedge funds.
Shares of AstraZeneca plc (NYSE AZN) opened at $33.82 on Wednesday. The company has a debt-to-equity ratio of 0.93, a current ratio of 0.80 and a quick ratio of 0.62. AstraZeneca plc has a 1-year low of $28.43 and a 1-year high of $36.70. The stock has a market cap of $85,738.52, a PE ratio of 14.27, a P/E/G ratio of 2.02 and a beta of 0.71.
The company also recently disclosed a semiannual dividend, which will be paid on Monday, March 19th. Investors of record on Friday, February 16th will be issued a $0.95 dividend. This represents a dividend yield of 5.62%. The ex-dividend date is Thursday, February 15th. AstraZeneca’s dividend payout ratio is currently 57.81%.
A number of equities research analysts have recently issued reports on AZN shares. JPMorgan Chase & Co. raised shares of AstraZeneca from a “neutral” rating to an “overweight” rating in a report on Friday, December 29th. Zacks Investment Research lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. BMO Capital Markets set a $38.00 target price on shares of AstraZeneca and gave the stock a “buy” rating in a report on Wednesday, January 10th. Leerink Swann reaffirmed a “market perform” rating and set a $36.00 target price (up previously from $33.00) on shares of AstraZeneca in a report on Thursday, January 18th. Finally, ValuEngine raised shares of AstraZeneca from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 3rd. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company’s stock. AstraZeneca currently has a consensus rating of “Hold” and a consensus target price of $36.26.
ILLEGAL ACTIVITY NOTICE: “NWQ Investment Management Company LLC Grows Stake in AstraZeneca plc (AZN)” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/03/14/nwq-investment-management-company-llc-grows-stake-in-astrazeneca-plc-azn.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.